bxpc-3 tumor model Search Results


orthotopic tumor models human pancreatic cancer cell lines bxpc3  (ATCC)
99
ATCC orthotopic tumor models human pancreatic cancer cell lines bxpc3
Figure 1. Combined Src and EGFR inhibition decreases tumor collagen content and reduces fibrosis in an orthotopic mouse model of PDAC. Orthotopic <t>BxPC3</t> (A) and PANC1 (B) tumor xenografts were established in nude mice (n ¼ 5 per group) and treated with vehicle, dasatinib (DST, 25 mg/kg/twice daily), erlotinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every 3 days) for 3 weeks prior to sacrifice. IHC was performed for collagen IV (Col IV) and trichrome blue (Trich blue) staining in xenograft tumor samples. Representative collagen IV and trichrome blue staining of BxPC3 (A, top) and PANC1 (B, top) xenograft tissues are shown (scale bar, 50 mm). Expression levels of collagen IV and trichrome blue were quantified from BxPC3 (A, bottom) and PANC1 (B, bot- tom) xenograft tissues and reported as percentage pos- itive staining of total area (ns, nonsignificant; , P < 0.01; , P < 0.001; , P < 0.0001).
Orthotopic Tumor Models Human Pancreatic Cancer Cell Lines Bxpc3, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bxpc-3+tumor+model/BxPC-3/10__1158_slash_1541___7786__mcr___19___0741-41-3-18
Average 99 stars, based on 1 article reviews
orthotopic tumor models human pancreatic cancer cell lines bxpc3 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
phenylmethylsulfonyl fluoride  (Enamine Ltd)
99
Enamine Ltd phenylmethylsulfonyl fluoride
Figure 1. Combined Src and EGFR inhibition decreases tumor collagen content and reduces fibrosis in an orthotopic mouse model of PDAC. Orthotopic <t>BxPC3</t> (A) and PANC1 (B) tumor xenografts were established in nude mice (n ¼ 5 per group) and treated with vehicle, dasatinib (DST, 25 mg/kg/twice daily), erlotinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every 3 days) for 3 weeks prior to sacrifice. IHC was performed for collagen IV (Col IV) and trichrome blue (Trich blue) staining in xenograft tumor samples. Representative collagen IV and trichrome blue staining of BxPC3 (A, top) and PANC1 (B, top) xenograft tissues are shown (scale bar, 50 mm). Expression levels of collagen IV and trichrome blue were quantified from BxPC3 (A, bottom) and PANC1 (B, bot- tom) xenograft tissues and reported as percentage pos- itive staining of total area (ns, nonsignificant; , P < 0.01; , P < 0.001; , P < 0.0001).
Phenylmethylsulfonyl Fluoride, supplied by Enamine Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bxpc-3+tumor+model/Phenylmethylsulfonyl+fluoride/custom%40en300-24380%4012850474
Average 99 stars, based on 1 article reviews
phenylmethylsulfonyl fluoride - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
tumor model human tumor cell lines  (ATCC)
97
ATCC tumor model human tumor cell lines
Figure 1. Combined Src and EGFR inhibition decreases tumor collagen content and reduces fibrosis in an orthotopic mouse model of PDAC. Orthotopic <t>BxPC3</t> (A) and PANC1 (B) tumor xenografts were established in nude mice (n ¼ 5 per group) and treated with vehicle, dasatinib (DST, 25 mg/kg/twice daily), erlotinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every 3 days) for 3 weeks prior to sacrifice. IHC was performed for collagen IV (Col IV) and trichrome blue (Trich blue) staining in xenograft tumor samples. Representative collagen IV and trichrome blue staining of BxPC3 (A, top) and PANC1 (B, top) xenograft tissues are shown (scale bar, 50 mm). Expression levels of collagen IV and trichrome blue were quantified from BxPC3 (A, bottom) and PANC1 (B, bot- tom) xenograft tissues and reported as percentage pos- itive staining of total area (ns, nonsignificant; , P < 0.01; , P < 0.001; , P < 0.0001).
Tumor Model Human Tumor Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bxpc-3+tumor+model/A2058/pm12655444-38-5-21
Average 97 stars, based on 1 article reviews
tumor model human tumor cell lines - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
zetasizer advance  (Malvern Panalytical)
99
Malvern Panalytical zetasizer advance
Figure 1. Combined Src and EGFR inhibition decreases tumor collagen content and reduces fibrosis in an orthotopic mouse model of PDAC. Orthotopic <t>BxPC3</t> (A) and PANC1 (B) tumor xenografts were established in nude mice (n ¼ 5 per group) and treated with vehicle, dasatinib (DST, 25 mg/kg/twice daily), erlotinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every 3 days) for 3 weeks prior to sacrifice. IHC was performed for collagen IV (Col IV) and trichrome blue (Trich blue) staining in xenograft tumor samples. Representative collagen IV and trichrome blue staining of BxPC3 (A, top) and PANC1 (B, top) xenograft tissues are shown (scale bar, 50 mm). Expression levels of collagen IV and trichrome blue were quantified from BxPC3 (A, bottom) and PANC1 (B, bot- tom) xenograft tissues and reported as percentage pos- itive staining of total area (ns, nonsignificant; , P < 0.01; , P < 0.001; , P < 0.0001).
Zetasizer Advance, supplied by Malvern Panalytical, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bxpc-3+tumor+model/Zetasizer+Advance/custom%40zetasizer-advance-01%4036089170
Average 99 stars, based on 1 article reviews
zetasizer advance - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
ivis optical imaging platform  (Revvity)
96
Revvity ivis optical imaging platform
Figure 1. Combined Src and EGFR inhibition decreases tumor collagen content and reduces fibrosis in an orthotopic mouse model of PDAC. Orthotopic <t>BxPC3</t> (A) and PANC1 (B) tumor xenografts were established in nude mice (n ¼ 5 per group) and treated with vehicle, dasatinib (DST, 25 mg/kg/twice daily), erlotinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every 3 days) for 3 weeks prior to sacrifice. IHC was performed for collagen IV (Col IV) and trichrome blue (Trich blue) staining in xenograft tumor samples. Representative collagen IV and trichrome blue staining of BxPC3 (A, top) and PANC1 (B, top) xenograft tissues are shown (scale bar, 50 mm). Expression levels of collagen IV and trichrome blue were quantified from BxPC3 (A, bottom) and PANC1 (B, bot- tom) xenograft tissues and reported as percentage pos- itive staining of total area (ns, nonsignificant; , P < 0.01; , P < 0.001; , P < 0.0001).
Ivis Optical Imaging Platform, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bxpc-3+tumor+model/IVIS+optical+imaging+platform/custom%40cls158738%4036089170
Average 96 stars, based on 1 article reviews
ivis optical imaging platform - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
ki67/mki67 antibody - bsa free  (Bio-Techne corporation)
96
Bio-Techne corporation ki67/mki67 antibody - bsa free
Figure 1. Combined Src and EGFR inhibition decreases tumor collagen content and reduces fibrosis in an orthotopic mouse model of PDAC. Orthotopic <t>BxPC3</t> (A) and PANC1 (B) tumor xenografts were established in nude mice (n ¼ 5 per group) and treated with vehicle, dasatinib (DST, 25 mg/kg/twice daily), erlotinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every 3 days) for 3 weeks prior to sacrifice. IHC was performed for collagen IV (Col IV) and trichrome blue (Trich blue) staining in xenograft tumor samples. Representative collagen IV and trichrome blue staining of BxPC3 (A, top) and PANC1 (B, top) xenograft tissues are shown (scale bar, 50 mm). Expression levels of collagen IV and trichrome blue were quantified from BxPC3 (A, bottom) and PANC1 (B, bot- tom) xenograft tissues and reported as percentage pos- itive staining of total area (ns, nonsignificant; , P < 0.01; , P < 0.001; , P < 0.0001).
Ki67/Mki67 Antibody Bsa Free, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bxpc-3+tumor+model/Ki67%2FMKI67+Antibody+-+BSA+Free/bio-techne+corporation___nb500-170
Average 96 stars, based on 1 article reviews
ki67/mki67 antibody - bsa free - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


Figure 1. Combined Src and EGFR inhibition decreases tumor collagen content and reduces fibrosis in an orthotopic mouse model of PDAC. Orthotopic BxPC3 (A) and PANC1 (B) tumor xenografts were established in nude mice (n ¼ 5 per group) and treated with vehicle, dasatinib (DST, 25 mg/kg/twice daily), erlotinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every 3 days) for 3 weeks prior to sacrifice. IHC was performed for collagen IV (Col IV) and trichrome blue (Trich blue) staining in xenograft tumor samples. Representative collagen IV and trichrome blue staining of BxPC3 (A, top) and PANC1 (B, top) xenograft tissues are shown (scale bar, 50 mm). Expression levels of collagen IV and trichrome blue were quantified from BxPC3 (A, bottom) and PANC1 (B, bot- tom) xenograft tissues and reported as percentage pos- itive staining of total area (ns, nonsignificant; , P < 0.01; , P < 0.001; , P < 0.0001).

Journal: Molecular Cancer Research

Article Title: Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer

doi: 10.1158/1541-7786.mcr-19-0741

Figure Lengend Snippet: Figure 1. Combined Src and EGFR inhibition decreases tumor collagen content and reduces fibrosis in an orthotopic mouse model of PDAC. Orthotopic BxPC3 (A) and PANC1 (B) tumor xenografts were established in nude mice (n ¼ 5 per group) and treated with vehicle, dasatinib (DST, 25 mg/kg/twice daily), erlotinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every 3 days) for 3 weeks prior to sacrifice. IHC was performed for collagen IV (Col IV) and trichrome blue (Trich blue) staining in xenograft tumor samples. Representative collagen IV and trichrome blue staining of BxPC3 (A, top) and PANC1 (B, top) xenograft tissues are shown (scale bar, 50 mm). Expression levels of collagen IV and trichrome blue were quantified from BxPC3 (A, bottom) and PANC1 (B, bot- tom) xenograft tissues and reported as percentage pos- itive staining of total area (ns, nonsignificant; , P < 0.01; , P < 0.001; , P < 0.0001).

Article Snippet: Cell lines and orthotopic tumor models Human pancreatic cancer cell lines BxPC3 and PANC1 were obtained from the ATCC and maintained according to the ATCC guidelines.

Techniques: Inhibition, Staining, Expressing

Figure 2. Combined Src and EGFR inhibition decreases STAT3 activity and enhances MVD in an orthotopic mouse model of PDAC. Histologic analysis was performed for pSTAT3 (A) and CD31 (B) in vehicle, dasatinib (DST, 25 mg/kg/ twice daily), erlotinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every 3 days) treated BxPC3 orthotopic tumor xenograft samples (n ¼ 3–5 per group; scale bar, 50 mm). pSTAT3 (A) and CD31 (B) positive expression levels were analyzed and reported as percentage positive staining of total area (ns, nonsig- nificant; , P < 0.05; , P < 0.001; , P < 0.0001).

Journal: Molecular Cancer Research

Article Title: Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer

doi: 10.1158/1541-7786.mcr-19-0741

Figure Lengend Snippet: Figure 2. Combined Src and EGFR inhibition decreases STAT3 activity and enhances MVD in an orthotopic mouse model of PDAC. Histologic analysis was performed for pSTAT3 (A) and CD31 (B) in vehicle, dasatinib (DST, 25 mg/kg/ twice daily), erlotinib (ERL, 50 mg/kg/daily), and/or gemcitabine (GEM, 15 mg/kg/every 3 days) treated BxPC3 orthotopic tumor xenograft samples (n ¼ 3–5 per group; scale bar, 50 mm). pSTAT3 (A) and CD31 (B) positive expression levels were analyzed and reported as percentage positive staining of total area (ns, nonsig- nificant; , P < 0.05; , P < 0.001; , P < 0.0001).

Article Snippet: Cell lines and orthotopic tumor models Human pancreatic cancer cell lines BxPC3 and PANC1 were obtained from the ATCC and maintained according to the ATCC guidelines.

Techniques: Inhibition, Activity Assay, Expressing, Staining